5 studies on Mc1r mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
**Alpha-MSH and KPV may offer a dual-action profile** — simultaneously controlling excessive inflammation while actively killing pathogens — that no conventional anti-inflammatory drug achieves. Standard NSAIDs and co…
**KPV's ability to suppress `NF-κB`-driven HIV transcription in primary macrophages** positions it as a mechanistically grounded candidate for adjunctive anti-HIV strategies targeting the macrophage reservoir — a comp…
**KPV's efficacy in two mechanistically distinct colitis models, including survival rescue in MC1R-null animals, meaningfully broadens its therapeutic relevance** beyond a single signaling pathway — a common liability…
**KPV and KdPT reframe the anti-inflammatory potential of α-MSH by stripping it down to a receptor-independent, pigmentation-free tripeptide** — a meaningful leap for any clinician or researcher frustrated by full-hor…